Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA).

Trial Profile

Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA).

Completed
Phase of Trial: Phase III

Latest Information Update: 10 May 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Overactive bladder; Urinary incontinence
  • Focus Therapeutic Use
  • Acronyms ROSETTA
  • Most Recent Events

    • 13 Jan 2017 Results published in the Journal of Urology.
    • 16 Sep 2016 Results of urinary biomarker analysis presented at the 46th Annual Meeting of the International Continence Society.
    • 23 Aug 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top